Penny Stock at Bottom of Nasdaq After Drug Data

CLSD's eye therapy drug failed a late-stage study

Managing Editor
Nov 5, 2018 at 9:55 AM
facebook twitter linkedin

The shares of Clearside Biomedical Inc (NASDAQ:CLSD) are down a whopping 52.7% to trade at $2.63 this morning, after Xipere, the company's eye therapy drug, failed a late-stage study. The drugmaker will discontinue the development of the combination therapy for retinal vein blockage, but will still file a marketing application for Xipere at year's end for treating uveitic macular edema. 

Out of the gate, CLSD fell to $2.49, a new record low. The shares have been carving out a channel of lower lows since mid-July, with their 30-day moving average containing any breakouts. Even prior to today's drop, the equity had shed 20% this year, and is on its way to a fifth straight losing month. 

Analysts have been undeterred by the drug stock's recent struggles. Currently, all five of the brokerages covering CLSD rate it a "strong buy," and its consensus 12-month price target sits all the way up at $23. For reference, the security hasn't traded near that level in almost two years. 

Short sellers have been piling on, though. Short interest increased by nearly 20% in the last two reporting periods to 1.05 million shares, the most since August 15. However, this only represents 3.5% of CLSD's total available float, indicating there is still ample room aboard the bearish bandwagon. Of course, the shares are on the short-sale restricted list today.


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners